NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ardelyx.comThe patent US8969377 for XPHOZAH, held by Ardelyx Inc, is set to expire on December 30, 2029. This patent is crucial for safeguarding the commercial viability of XPHOZAH, a medication indicated for the treatment of conditions such as irritable bowel syndrome, chronic kidney disease, and end-stage renal disease. The expiration could significantly impact Ardelyx's revenue, as it may open the market to generic competition, thereby affecting pricing and sales of the product.
Patent ExpirationThe expiration of US Patent 9408840 for IBSRELA, a product of Ardelyx Inc, is scheduled for December 30, 2029. This patent covers compounds used for treating conditions such as irritable bowel syndrome and chronic kidney disease. The expiration of this patent may open the market for generic versions of the drug, potentially impacting Ardelyx's revenue and market position in the gastrointestinal treatment sector.
Patent ExpirationThe patent US9006281 related to Ardelyx Inc's product IBSRELA is set to expire on May 2, 2030. IBSRELA is designed for the treatment of irritable bowel syndrome as well as chronic kidney disease and end-stage renal disease. This expiration may lead to increased competition and potential revenue impacts for Ardelyx, impacting market dynamics for its product offerings.
patent expirationPatent US8541448 for XPHOZAH, assigned to Ardelyx Inc, is set to expire on August 1, 2033. XPHOZAH is designed to treat disorders related to fluid retention and salt overload, including congestive heart failure, chronic kidney disease, and hypertension. The expiration of this patent may lead to increased competition from generic alternatives in the treatment of these conditions, potentially impacting Ardelyx's market position and revenue streams.
Patent ExpirationThe patent US8541448 for Ardelyx Inc's drug IBSRELA is set to expire on August 1, 2033. IBSRELA is designed to treat disorders associated with fluid retention or salt overload, including conditions such as heart failure, chronic kidney disease, and gastrointestinal tract disorders. The expiration of this patent may allow for the introduction of generic alternatives, which could impact Ardelyx's market share and revenue in the related therapeutic areas.
patent expirationThe patent US10940146 for XPHOZAH, a product developed by Ardelyx Inc, is set to expire on April 10, 2034. This patent covers NHE3-binding and/or NHE3-modulating agents that act as phosphate transport inhibitors, impacting phosphate transport in the gastrointestinal tract and kidneys. The expiration may influence Ardelyx's competitive position in the market as generic alternatives could enter, potentially affecting the company's revenue from XPHOZAH.
Patent Expiration